BACKGROUND: The purpose of the current study was to investigate the association between insulin resistance (which was measured using fasting blood C-peptide) and its joint association with insulin-like growth factors (IGF-1, IGF-2, and IGF binding protein-3 [IGFBP-3]) on the risk of breast carcinoma. METHODS: Included in the current study were 400 case-control pairs from the Shanghai Breast Cancer Study. Pretreatment biospecimens and interview data were collected from all breast carcinoma cases and their individually matched controls. RESULTS: Breast carcinoma risk was found to be statistically significantly increased when higher blood levels of C-peptide and IGFs were noted in a dose-response manner. There was a statistically significant twofold to threefold increased risk of breast carcinoma for women in the highest quartile of C-peptide, IGF-1, or IGFBP-3 compared with women in the lowest quartiles. Women with high levels of both C-peptide and IGF-1 or IGFBP-3 also were found to have a substantially higher risk of breast carcinoma than those women with a high level of only one of these molecules. The adjusted odds ratios (ORs) were 3.79 (95% confidence interval [95% CI], 2.03-7.08) for those with a higher level of both C-peptide and IGF-1 and 4.03 (95% CI, 2.06-7.86) for those with a higher level of both C-peptide and IGFBP-3. CONCLUSIONS: The results of the current study suggest that insulin resistance and IGFs may synergistically increase the risk of breast carcinoma. Copyright 2004 American Cancer Society.
BACKGROUND: The purpose of the current study was to investigate the association between insulin resistance (which was measured using fasting blood C-peptide) and its joint association with insulin-like growth factors (IGF-1, IGF-2, and IGF binding protein-3 [IGFBP-3]) on the risk of breast carcinoma. METHODS: Included in the current study were 400 case-control pairs from the Shanghai Breast Cancer Study. Pretreatment biospecimens and interview data were collected from all breast carcinoma cases and their individually matched controls. RESULTS:Breast carcinoma risk was found to be statistically significantly increased when higher blood levels of C-peptide and IGFs were noted in a dose-response manner. There was a statistically significant twofold to threefold increased risk of breast carcinoma for women in the highest quartile of C-peptide, IGF-1, or IGFBP-3 compared with women in the lowest quartiles. Women with high levels of both C-peptide and IGF-1 or IGFBP-3 also were found to have a substantially higher risk of breast carcinoma than those women with a high level of only one of these molecules. The adjusted odds ratios (ORs) were 3.79 (95% confidence interval [95% CI], 2.03-7.08) for those with a higher level of both C-peptide and IGF-1 and 4.03 (95% CI, 2.06-7.86) for those with a higher level of both C-peptide and IGFBP-3. CONCLUSIONS: The results of the current study suggest that insulin resistance and IGFs may synergistically increase the risk of breast carcinoma. Copyright 2004 American Cancer Society.
Authors: S E Hankinson; W C Willett; G A Colditz; D J Hunter; D S Michaud; B Deroo; B Rosner; F E Speizer; M Pollak Journal: Lancet Date: 1998-05-09 Impact factor: 79.321
Authors: M E Del Giudice; I G Fantus; S Ezzat; G McKeown-Eyssen; D Page; P J Goodwin Journal: Breast Cancer Res Treat Date: 1998-01 Impact factor: 4.872
Authors: Lital Keinan-Boker; H Bas Bueno De Mesquita; Rudolf Kaaks; Carla H Van Gils; Paul A H Van Noord; Sabina Rinaldi; Elio Riboli; Jaap C Seidell; Diederick E Grobbee; Petra H M Peeters Journal: Int J Cancer Date: 2003-08-10 Impact factor: 7.396
Authors: P F Bruning; J Van Doorn; J M Bonfrèr; P A Van Noord; C M Korse; T C Linders; A A Hart Journal: Int J Cancer Date: 1995-07-28 Impact factor: 7.396
Authors: H Yu; M A Levesque; M J Khosravi; A Papanastasiou-Diamandi; G M Clark; E P Diamandis Journal: Int J Cancer Date: 1998-12-18 Impact factor: 7.396
Authors: Thomas P Ahern; Susan E Hankinson; Walter C Willett; Michael N Pollak; A Heather Eliassen; Rulla M Tamimi Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10 Impact factor: 4.254
Authors: Alecia Malin Fair; Qi Dai; Xiao-Ou Shu; Charles E Matthews; Herbert Yu; Fan Jin; Yu-Tang Gao; Wei Zheng Journal: Cancer Detect Prev Date: 2007-07-23